Certifications are now available!
Welcome and Chairs Remarks
A. Kotsakis, Ph. Koinis
Chairs: N. Tsoukalas, D. Papageorgiou
11.50-12.20
Abstract 1501 | Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation
Abstract 1504 | Prior authorizations for oral anticancer drugs and delayed prescription fills.
Abstract 1507 | A cognitive behavioral digital therapeutic for anxiety and depression in patients with cancer: A decentralized randomized controlled trial.
E. Arvanitou
12.20-12.40
Abstract 12000 | A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.
Abstract 12001 | Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
M. Lavdaniti
12.40-13.00
Abstract 12006 | Reduced symptom burden after implementation of an electronic symptom management program.
Abstract 12008 | Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.
Ch. Ntola
13.00-13.15 Discussion Ν. Tsoukalas, D. Papageorgiou
Chairs: A. Kotsakis, G. Rigakos
13.15-13.55
Abstract LBA6002 | PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)
Abstract 6007 | Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.
Abstract 6003 | Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
Abstract 6005 | Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
P. Katsaounis
13.55-14.10 Discussant A. Psyrri
Light Lunch
Chairs: Ch. Kosmas, Ch. Panopoulos
Screening Patients at High Risk of Developing Pancreatic Cancer A. Stribakos
Chairs: E. Razis, S. Labropoulos
15.30-15.50
Abstract LΒΑ1 | INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
Abstract 2009 | Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.
A. Vernardou
15.50-16.10
Abstract 2012 | External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
Abstract 2008 | Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.
M. Avgoustidou
16.10-16.20 Discussant E. Razis
Coffee Break
Chairs: D. Kanaloupiti, S. Karageorgopoulou
17.00-17.20
Abstract LBA 500 | Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
Abstract 501 | Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
K. Rapti
17.20-17.40
Abstract 503 | Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
Abstract 517 | Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.
Α. Sfika
17.40-17.50 Discussant D. Tryfonopoulos
Chairs: V. Barbounis, I. Kotteas
17.50-18.10
Abstract 1003 | Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
Abstract 1007 | Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
N. Asimakopoulou
18.10-18.30 Abstract LBA 1000 | Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
Abstract 1006 | An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
V. Aidarinis
18.30-18.40 Discussant E. Galani
Chairs: M. Nikolaou, Ph. Koinis
09.00-09.20
Abstract 2503 | Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
Abstract 2504 | Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
D. Zouki
09.20-09.40
Abstract 2509 | Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.
Abstract 2510 | First-line treatment of fecal microbiota transplantation for immune-mediated colitis.
G. Ardavanis-Loukeris
09.40-09.50 Discussion
Chairs: V. Georgoulias, A. Psyrri
09.50-10.10
Abstract LBA 3000 | Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
Abstract 3003 | Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.
E. Kontopodis
10.10-10.30
Abstract 3004 | Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.
Abstract 3006 | Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase ½ a study.
S. Talagani
10.30-10.40 Discussion
Coffee Break
Chairs: I. Samaras, F.I. Dimitrakopoulos
11.00-11.20
Abstract LBA 2 | PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Abstract 3508 | Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
M. Drizou
11.20-11.40
Abstract 3520 | Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.
Abstract 3528 |HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.
A. Markou
11.40-12.10
Abstract 4008 | Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
Abstract 4009 | Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
Abstract 4006 | Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.
E. Eleftherakis-Papaiakovou
12.10-12.40 Discussant G. Papaxoinis
Chairs: Th. Karambeazis, P. Katsaounis
Emerging Therapies for Colorectal Cancer V. Papadopoulos
Chairs: A. Tzovaras, S. Kokkali
13.10-13.30
Abstract LBA 9503 | Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
Abstract 9506 | Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).
J. Duran - Moreno
13.30-13.50
Abstract LBA 9505 | Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
Abstract 101 | The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
D. Ziogas
13.50-14.00 Discussion
Chairs: A. Boutis, I. Pateras
Family Matters: Germline Testing in Thoracic Cancers N. Mala
Light Lunch
Chairs: V. Ramfidis, J. Duran-Moreno
15.20-15.40
Abstract 11503 | A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
Abstract 11524 | Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
S. Kokkali
15.40-15.50 Discussant J. Duran - Moreno
Chairs: Ch. Papadimitriou, V. Papadopoulos
15.50-16.20
Abstract LBA 5511 | An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
Abstract 5503 | Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Abstract 5509 | Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.
M. Rovithi
16.20-16.30 Discussant V. Papadopoulos
Chairs: E. Samantas, G. Oikonomopoulos
16.30-16.50
Abstract LBA 100 | KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
Abstract LBA 3 | OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIA NSCLC
E. Fergadis
16.50-17.10
Abstract 8512 | Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).
Abstract LBA 8505 | IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
O. Fiste
17.10-17.20 Discussant Α. Kyriazoglou
Chairs: A. Kotsakis, Ph. Koinis
17.20-17.40
Abstract LBA 9000 | Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
Abstract 9004 | TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
D. Stefanou
17.40-18.00
Abstract LBA 9005 | Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
Abstract 9006 | The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L).
E. Karatrasoglou
18.00-18.10 Discussant An. Grivas
Coffee Break
Chairs: K. Koutsoukos, K. Tsapakidis
18.40-19.00
Abstract LBA 4500 | Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
Abstract LBA 4507 | Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
Th. Tegos
19.00-19.20
Abstract 4508 | SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
Abstract LBA 4501 | Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.
E. Christakou
19.20-19.40
Abstract LBA 5000 | Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
Abstract 5004 | TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
Abstract 5006 | Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.
N. Cholis
19.40-19.50 Discussant E. Lianos
Closing Remarks
